Acura Pharmaceuticals, Inc. (ACUR)
Stock Price:
$0.2750 USD
0.0050 (1.85%)
Updated November 24, 1:58 PM EST - Market open
Key Info
| Market Cap |
5.95M |
| Revenue (ttm) |
4.07M |
| Net Income (ttm) |
-810,000 |
| Shares Out |
21.65M |
| EPS (ttm) |
-0.03 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 24 |
| Last Price |
$0.2750 |
| Previous Close |
$0.2700 |
| Change ($) |
0.0050 |
| Change (%) |
1.85% |
| Day's Open |
0.2800 |
| Day's Range |
0.2700 - 0.2950 |
| Day's Volume |
11,227 |
| 52-Week Range |
0.14 - 0.4679 |
More Stats
| Market Cap |
5.95M |
| Enterprise Value |
11.73M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
21.65M |
| Float |
7.49M |
| EPS (basic) |
-0.01 |
| EPS (diluted) |
-0.03 |
| FCF / Share |
0.00 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
89,846 |
| Short Ratio |
0.73 |
| Short % of Float |
1.20% |
| Beta |
0.91 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
1.46 |
| PB Ratio |
n/a |
| Revenue |
4.07M |
| Operating Income |
-358,000 |
| Net Income |
-810,000 |
| Free Cash Flow |
-117,000 |
| Net Cash |
-5.78M |
| Net Cash / Share |
-0.27 |
| Gross Margin |
28.29% |
| Operating Margin |
-8.79% |
| Profit Margin |
-19.90% |
| FCF Margin |
-2.87% |
| ROA |
8.31% |
| ROE |
n/a |
| ROIC |
-11.70% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
6.00
Current: $0.2750
High
6.00
Target: 6.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 2.66 | 0.41 | 2.97 | 4.46 | 8.59 | 0.75 | 0.12 | - | 20.47 | 3.31 |
| Revenue Growth | 548.05% | -86.18% | -33.56% | -48.01% | 1043.41% | 510.57% | - | - | 518.12% | - |
| Gross Profit | 2.66 | 0.41 | 2.84 | 4.01 | 7.93 | 0.32 | -0.24 | - | 20.47 | 3.31 |
| Operating Income | -0.73 | -3.92 | -5.23 | -6.56 | -4.00 | -12.20 | -14.09 | -9.74 | 10.53 | -12.72 |
| Net Income | -3.77 | -3.84 | -5.68 | -7.39 | -4.99 | -13.21 | -13.90 | -9.67 | 10.39 | -12.71 |
| Shares Outstanding | 26.72 | 21.15 | 15.90 | 11.87 | 10.80 | 9.78 | 9.55 | 9.50 | 9.50 | 9.41 |
| Earnings Per Share | -0.14 | -0.18 | -0.36 | -0.62 | -0.46 | -1.35 | -1.45 | -1.00 | 1.10 | -1.35 |
| Operating Cash Flow | -0.62 | -3.91 | -4.51 | -5.56 | -3.69 | -11.04 | -13.68 | -7.04 | 12.31 | -6.48 |
| Capital Expenditures | - | - | 0.31 | -0.08 | -0.20 | -2.14 | -0.02 | -0.15 | -0.13 | -0.04 |
| Free Cash Flow | -0.62 | -3.91 | -4.20 | -5.64 | -3.89 | -13.18 | -13.70 | -7.19 | 12.18 | -6.52 |
| Cash & Equivalents | 0.86 | 0.09 | 2.22 | 5.18 | 13.32 | 12.10 | 26.07 | 27.42 | 35.69 | 24.05 |
| Total Debt | 6.00 | 4.22 | 2.69 | 5.36 | 7.75 | 9.56 | 9.60 | - | - | - |
| Net Cash / Debt | -5.14 | -4.13 | -0.47 | -0.17 | 5.57 | 2.54 | 16.47 | 27.42 | 35.69 | 24.05 |
| Assets | 2.56 | 2.15 | 4.60 | 8.21 | 16.96 | 16.03 | 28.63 | 29.06 | 37.17 | 25.49 |
| Liabilities | 7.30 | 5.77 | 4.63 | 7.03 | 9.06 | 10.98 | 10.71 | 1.43 | 0.53 | 1.15 |
| Book Value | -4.74 | -3.62 | -0.03 | 1.18 | 7.90 | 5.05 | 17.92 | 27.63 | 36.64 | 24.34 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Acura Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
12 |
| CEO |
Robert B. Jones |
Stock Information
| Ticker Symbol |
ACUR |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers—Specialty & Generic |
| Unique Identifier |
OTCMKTS: ACUR |
Description
Acura Pharmaceuticals, a specialty pharmaceutical company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was founded in 1935 and is based in Palatine, Illinois.